Abstract
Breaking Insights| October 04 2022 Highlights from Recent Cancer Literature Author & Article Information Online ISSN: 1538-7445 Print ISSN: 0008-5472 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Res (2022) 82 (19): 3407–3408. https://doi.org/10.1158/0008-5472.CAN-82-19-BI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record October 4 2022 Citation Highlights from Recent Cancer Literature. Cancer Res 1 October 2022; 82 (19): 3407–3408. https://doi.org/10.1158/0008-5472.CAN-82-19-BI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search The final and critical step of metastasis is colonization in a secondary tissue, which requires suppression of the immune system to prevent tumor cell clearance. Gong and colleagues used mouse models of breast cancer metastasis to investigate whether an immunosuppressive niche in the lung supports metastasis. They found that in the lung, dendritic cell antigen presentation and T-cell stimulation were reduced compared with other organ tissues, due to a population of fibroblasts that expressed PTGS2, the gene encoding cyclooxygenase 2 (COX2), which converts arachidonic acid to prostaglandin E2 (PGE2). Neutrophils, often found at the sites of metastatic cancers, were found to produce high amounts of IL1β that boosted the expression of PTGS2 in lung fibroblasts. The generation of PGE2 was critical for the immunosuppressive activity of the lung fibroblasts, as receptor antagonists for PGE2 could reverse the immunosuppressive phenotype in the lung. Furthermore, blocking the activity of PGE2 synergized... You do not currently have access to this content.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
